Teva (TEVA) Rumored to Slash Up to 6,000 Jobs, Company Says Numbers Are Incorrect
Drug Giant Amgen (AMGN) to Create Hundreds of New Jobs in Florida
Turns Out Editas Medicine (EDIT)'s R&D Deal With Allergan (AGN) Could be Worth $1 Billion
How Biogen (BIIB) Spinoff Bioverativ (BIVVV) and Its Hemophilia Med Could Make This Biotech Bleed
GlaxoSmithKline (GSK), Regeneron (REGN) Join Hands to Decode the DNA of 500,000 Britons
Johnson & Johnson (JNJ), GlaxoSmithKline (GSK) Yank Ads From YouTube
Bay Area's Ultragenyx (RARE) Tanks as Seizure Drug Flunks Phase II Test
UCSF Heart Doctor Wary of Amgen (AMGN)-Paid Repatha Study
5 Biotechs the Super-Rich Are Favoring in 2017 (So Far)
Biogen (BIIB)'s Victory Over $4 Billion MS Patent Spat Makes Company an Even More Attractive M&A Target
5 Biotechs That Have Major Catalysts Coming in the Next 6 to 9 Months
Novartis AG (NVS)'s Phase III Drug for Heart Failure Bombs Trial
Reverse Merger With Dare Bioscience Gives Cerulean (CERU) Execs a Parting Gift—Bonuses
Facebook Hiring Dozens for Secretive Division, Rumored to be Working on Brain-Scanning Technology and Other Med Device
Why Struggling Bristol-Myers Squibb (BMY) Could Take Out This Danish Biotech in Major €500M Deal
How This Drug Candidate Could be a Winner in Gilead (GILD)'s Pipeline
4 Small-Cap Biotechs to Consider if Gilead (GILD) Isn’t Doing it For You
Questions Arise Over This Bay Area Biotech CEO's Doctorate Degree and His Time at the University of Pennsylvania
See All News >
Facebook Hiring Dozens for Secretive Division, Rumored to be Working on Brain-Scanning Technology and Other Med Device
Why Struggling Bristol-Myers Squibb (BMY) Could Take Out This Danish Biotech in Major €500M Deal
How This Drug Candidate Could be a Winner in Gilead (GILD)'s Pipeline
4 Small-Cap Biotechs to Consider if Gilead (GILD) Isn’t Doing it For You
Questions Arise Over This Bay Area Biotech CEO's Doctorate Degree and His Time at the University of Pennsylvania
Heat Biologics (HTBX) Rockets as Lung Cancer Med Hits Mid-Stage Goals
Ex-Novartis AG (NVS) Exec to Take the Reins at Bay Area's Forty Seven on May 1
Former Celgene (CELG) Exec to Helm Cipher Pharma (DND.TO)
Filings Reveal Alnylam (ALNY) CEO's Pay Dropped Almost 80% in 2016
For Sale: Nektar Therapeutics (NKTR) Plans to License Hot New Opioid Drug
Cerulean (CERU) to Slash More Than Half of Its Remaining Staff, Merge With SoCal Biotech
3 Beaten-Up Biotech Stocks: Are They Bargains?
Esperion (ESPR) Hits A New High After Positive Feedback For Its Heart Drug From The FDA
Anti-PCSK9 Drugs: An Ingenious Solution For A Problem That's Mostly Already Solved
Ex-GlaxoSmithKline (GSK) Scientists' Pulmocide Hauls in $30.4 Million
Investors Squeal With Delight as Eli Lilly (LLY)'s Breast Cancer Combo Succeeds in Phase III, Faces Tough Competition from Pfizer (PFE) and Novartis AG (NVS)
Trump Budget Would Double FDA Product Review Fees, Leading to Faster Drug Approvals
Is There A Link Between Climate Change And Diabetes? Leiden University Medical Center Study Reveals
See All News >
//-->